Latent tuberculosis infection: Diagnosis and treatment

Harefuah

Volumn 141, Issue 3, 2002, Pages 233-236+316

  Bendayan, D ^a   Raz, M ^a   Kramer, M R ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Latent tuberculosis infection; Targeted tuberculin test; Tuberculosis

Indexed keywords

BCG VACCINE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ARTICLE; BCG VACCINATION; HIGH RISK POPULATION; HUMAN; IMMUNE STATUS; MYCOBACTERIUM TUBERCULOSIS; RISK FACTOR; TUBERCULIN TEST; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BCG VACCINE; HUMANS; ISONIAZID; PREDICTIVE VALUE OF TESTS; PYRAZINAMIDE; RIFAMPIN; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0036070753     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Global tuberculosis incidence and mortality during 1990-2000
2. Global epidemiology of tuberculosis
3. Airborne infection
4. The immunology of mycobacterial diseases
5. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care facilities
6. Infectiousness of a university student with laryngeal and cavitary tuberculosis
7. Contacts of active pulmonary tuberculosis
8. Diagnostic standards and classification of tuberculosis in adults and children
9. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus
10. Tuberculosis in heart transplant recipients
11. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid treated asthmatic population
12. Silicosis and risk of lung cancer or lung tuberculosis: A cohort study
13. The tuberculin skin test
14. Tuberculin test, preventive therapy, and elimination of tuberculosis
15. False tuberculin test results
16. Targeted tuberculin testing and treatment of latent tuberculosis infection
17. Controlled chemoprophylaxis trials in tuberculosis: A general review
18. The ten-year incidence of clinical tuberculosis following "conversion" in 2,550 individuals aged 14 to 19 years
19. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts
20. Efficacy of various durations of isoniazid prevention therapy for tuberculosis: Five years of follow-up in the IUAT trial
21. Treatment of tuberculosis and tuberculosis infection in adults and children
22. How much isoniasid is needed for prevention of tuberculosis among immunocompetent adults
23. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
24. A trial of three regimens to prevenrt tuberculosis in Ugandan adults infected with human immunodeficiency virus
25. Isoniazid associated hepatitis: Report of an outbreak
26. Isoniazid associated hepatitis deaths: A review of awailable information
27. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV infected persons
28. Rifampin and isoniazid prophylactic chemotherapy for tuberculosis
29. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations